Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Role of Genetic Testing in the Selection of Therapy for Breast Cancer

25 Aug 2016

Abstract excerpt

IMPORTANCE: The application of next-generation sequencing (NGS) genomic testing for somatic mutations in breast oncology has been slower than anticipated due to issues with clinical applicability and natural heterogeneity of breast cancer. This review summarizes the state of the field and considers approaches for more effective implementation. OBSERVATIONS: While there is an emerging role for germline genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Cancer Treatment Studies
Share to Cancer Genomics and Diagnostics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27560719
DOI: 10.1001/jamaoncol.2016.2719

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Role of Genetic Testing in the Selection of Therapy for Breast CancerPMID 27560719Read ↗

Clinical implications of breast cancer tumor genomic testing.Semantic proximity Read ↗

Evolutionary Overview and Future Perspectives: ESR1 Mutations, Liquid Biopsy, and Artificial Intelligence for a New Era of Personalized Medicine in ER+ Breast Cancer.Semantic proximity Read ↗

Circulating tumor DNA in breast cancer: a biomarker for patient selection.Semantic proximity Read ↗

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.Semantic proximity Read ↗

Next-generation sequencing in breast cancer: current clinical applications and future directionsSemantic proximity Read ↗

Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.Semantic proximity Read ↗

Assessment of genome mutation analysis for tumor-informed detection of circulating tumor DNA in patients with breast cancer.Semantic proximity Read ↗

Molecular Testing in Breast Cancer: A Guide to Current Practices.Semantic proximity Read ↗

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast CancerSemantic proximity Read ↗

Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.Semantic proximity Read ↗

Genetic Signature of Breast Cancer Defines Therapeutic Interventions and Indicates Early Drug Resistance.Semantic proximity Read ↗

Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.